This webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Colorectal, Hepatocellular, Pancreatic, and Gastric/Esophageal Cancers.

This recorded webinar is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Colorectal Cancer.

Because patients with locally advanced rectal cancer are at high risk for both recurrence and distant disease, they require adjuvant therapy. In the United States, the current standard of care is neoadjuvant chemoradiation followed by surgery and adjuvant chemotherapy.

The Westin Diplomat
Hollywood, Florida

This congress is a full-day educational program designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Gastrointestinal Cancers.

This 60-minute webinar, which will be offered on four (4) different occasions, is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Colorectal Cancer.

This 60-minute webinar, which will be offered on four (4) different occasions, is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Colorectal Cancer.

This 60-minute webinar, which will be offered on four (4) different occasions, is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Colorectal Cancer.

This 60-minute webinar, which will be offered on four (4) different occasions, is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Colorectal Cancer.

The molecular analysis of biomarkers in oncology is rapidly advancing, but the incorporation of new molecular tests into clinical practice will require a greater understanding of the genetic changes that drive malignancy, the assays used to measure the resulting phenotypes and genotypes, and the